IT IS THE MOST BETA 1 -SELECTIVE ADRENOCEPTOR ANTAGONIST CURRENTLY AVAILABLE FOR CLINICAL USE AND HAS NO ALFA 1-BLOCKING ACTION. IT IS DEVOID OF INTRINSIC SYMPATHOMIMETIC OR MEMBRANE STABILIZING ACTIVITY AND BETA-ADRENERGIC BLOCKING ACTIVITY WITH A VASODILATING EFFECT MEDIATED BY THE ENDOTHELIAL L-ARGININE NO PATHWAY, THE PROPERTY NOT SHARED BY OTHER BETA-BLOCKERS. NEBIVOLOL IMPROVES ARTERIAL COMPLIANCE AND LEFT VENTRICULAR(LV) FUNCTION IN PATIENTS WITH HEART FAILURE. TREATMENT WITH NEBIVOLOL PRESERVES LV FUNCTION AND CAN REDUCE LV MASS IN HYPERTENSIVE PATIENTS WITH LV HYPERTROPHY. BESIDES SIGNIFICANT REDUCTION IN TRIGLYCERIDES (13 %) WITH NEBIVOLOL CHOLESTEROL ALSO FOUND TO BE DECREASED BY 8% IN HYPERTENSIVES. IN HYPERTENSIVE WITH DIABETIC PATIENTS NEBIVOLOL HAD THE MOST FAVORABLE EFFECTS IN TERMS OF DECREASE IN TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE BY 18%, 9% AND 16% RESPECTIVELY. A DIRECT ACTION OF NEBIVOLOL ON THE VASCULAR ENDOTHELIUM, TOGETHER WITH ITS EFFECTIVENESS AS A BETA-BLOCKER, MAY THEREFORE BE BENEFICIAL IN PATIENTS WITH ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH HYPERTENSION, DIABETES MELLITUS AND HYPERCHOLESTEROLAEMIA. THUS TREATMENT WITH NEBIVOLOL MAY SLOW, OR EVEN PREVENT SOME OF THE VASCULAR COMPLICATIONS OF HYPERTENSION.